P1.04-02 Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy With PD1 Checkpoint Blockade

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.717
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Preclinical Evidence That PD1 Blockade Cooperates With Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors

Cancer Research
Cancer ResearchOncology
2014English

Overcoming Resistance to Checkpoint Blockade Therapy by Targeting PI3Kγ in Myeloid Cells

Nature
Multidisciplinary
2016English

Understanding the Role of PD-L1/PD1 Pathway Blockade and Autophagy in Cancer Therapy

OncoTargets and Therapy
OncologyPharmacology
2017English

Targeting Tumor-Intrinsic Hexosamine Biosynthesis Sensitizes Pancreatic Cancer to Anti-Pd1 Therapy

Journal of Clinical Investigation
Medicine
2019English

Unwrapping the Genomic Characteristics of Urothelial Bladder Cancer and Successes With Immune Checkpoint Blockade Therapy

Oncogenesis
Cancer ResearchMolecular Biology
2018English

Checkpoint Blockade Therapy Resistance in Hodgkin's Lymphoma

The Lancet
Medicine
2018English

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

Cancer Cell
Cancer ResearchOncologyCell Biology
2018English

Carnosic Acid and Fisetin Combination Therapy Enhances Inhibition of Lung Cancer Through Apoptosis Induction

International Journal of Oncology
Cancer ResearchOncology
2017English

TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination With Anti-Pd1 and Anti-Cd137 Immunostimulatory Monoclonal Antibodies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy